miCure Therapeutics

Company Overview

Snapshot

Founded in September 2013, miCure Therapeutics operates with 1–10 employees. The company has raised $2M across one funding round. miCure Therapeutics specializes in microRNA-based therapeutics and diagnostics for neurodegenerative and psychiatric disorders, including its miR-135 product for mood disorders.

Business overview

miCure Therapeutics is a biotechnology company focused on developing microRNA-based therapeutics and diagnostics for central nervous system (CNS) disorders. Its core technology leverages inventions from the Weizmann Institute of Science, particularly targeting neurodegenerative and psychiatric conditions. The company's lead product, miR-135, is being developed to address mood disorders, including major depression and treatment-resistant depression, by modulating key gene transcripts involved in serotonergic neuronal activity. miCure Therapeutics operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, and serves the healthcare and life sciences industries.

Company Intelligence Q&A

What is miCure Therapeutics' primary focus?

miCure Therapeutics focuses on developing microRNA-based therapeutics and diagnostics for neurodegenerative and psychiatric disorders, leveraging inventions from the Weizmann Institute of Science.

What is miCure Therapeutics' lead product?

miCure Therapeutics' lead product is miR-135, which is being developed to treat mood disorders, including major depression and treatment-resistant depression.

What is the status of miCure Therapeutics?

miCure Therapeutics is currently non-active and ceased to operate in March 2026.

When was miCure Therapeutics founded?

miCure Therapeutics was founded in September 2013.

What is the total capital raised by miCure Therapeutics?

miCure Therapeutics has raised $2M across one funding round.